<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287478</url>
  </required_header>
  <id_info>
    <org_study_id>APT.UTI.001</org_study_id>
    <nct_id>NCT04287478</nct_id>
  </id_info>
  <brief_title>Bacteriophage Therapy in Patients With Urinary Tract Infections</brief_title>
  <official_title>A Phase I/II Study of Bacteriophage Therapy to Evaluate Safety, Tolerability, and Efficacy of Targeted &quot;Personalized&quot; Bacteriophage Treatments in Patients With Bacterial Infection of the Urinary Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adaptive Phage Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Adaptive Phage Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II trial designed to evaluate bacteriophage therapy in patients with
      urinary tract infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and efficacy of bacteriophage therapy in patients with
      urinary tract infection (UTI). Patients to be enrolled will have urinary tract infections due
      to E. coli and K. pneumoniae. This will include asymptomatic patients with neurogenic bladder
      and symptomatic patients with complicated urinary tract infections who are at risk of UTI
      recurrence. Patients will be followed for bacterial clearance or recurrence of urinary tract
      infection.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Initially, patients with neurogenic bladder and urinary tract infections will be enrolled and followed for bacterial eradication. Results from this cohort will be used to confirm or modify the phage dosing regimen before proceeding to the patients with symptomatic infection at risk of recurrence. The trial will use pre-specified criteria to determine what phage regimens should be evaluated.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Patient will be randomized to receive either active phage or placebo treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Identify ideal bacteriophage treatment regimens based on improvements in disease control rates</measure>
    <time_frame>baseline</time_frame>
    <description>Microbiological eradication of target pathogen identified at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the safety of bacteriophage therapy</measure>
    <time_frame>At least 56 days</time_frame>
    <description>Safety will be measured by the number and percent of treatment related adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the tolerability of bacteriophage therapy</measure>
    <time_frame>At least 56 days</time_frame>
    <description>Tolerability will be measured by the percentage of patients who discontinue treatment due to adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Recurrence of urinary tract infection</measure>
    <time_frame>1 year</time_frame>
    <description>Recurrence of urinary tract infection for 1 year</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Urinary Tract Infection Bacterial</condition>
  <arm_group>
    <arm_group_label>Intravenous (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phage administered via the intravenous route.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravesical (IVS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phage administered via the intravesical route.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selected phage for E. coli administered via selected route based on previous Arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selected phage for Klebsiella pneumoniae administered via selected route based on previous Arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selected phage for E. coli administered via selected route based on previous Arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selected phage for Klebsiella pneumoniae administered via selected route based on previous arms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bacteriophage Therapy</intervention_name>
    <description>Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing</description>
    <arm_group_label>Intravenous (IV)</arm_group_label>
    <arm_group_label>Intravesical (IVS)</arm_group_label>
    <arm_group_label>Subcohort A</arm_group_label>
    <arm_group_label>Subcohort B</arm_group_label>
    <arm_group_label>Subcohort C</arm_group_label>
    <arm_group_label>Subcohort D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          -  Males or females ≥18 years of age.

          -  Female patients of childbearing potential.

          -  Male patients must agree not to donate sperm up for one month.

          -  English-speaking.

        General Exclusion Criteria:

          -  Stage 4 or greater chronic kidney disease (CKD).

          -  Abnormal liver function tests &gt;3×upper limit of normal (ULN).

          -  Other conditions which could confound study results.

          -  Body mass index of &gt; 40 or weight less than 50 kg.

          -  Known allergy to phage products.

          -  Pregnant and/or breastfeeding.

          -  Immunocompromised.

          -  Need for antiviral medication.

          -  History of severe autonomic dysreflexia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Hopkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VP Clinical Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Holland</last_name>
    <phone>202-391-8058</phone>
    <email>sholland@aphage.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antimicrobial Resistance</keyword>
  <keyword>Bacteriophage</keyword>
  <keyword>Urinary Tract Infections</keyword>
  <keyword>Phage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

